ABCG2 and breast cancer: Our results provide evidence that ABCG2 polymorphisms are associated with BC susceptibility and therapeutic outcome of anthracycline-based NCT and postoperative chemotherapies in a large and well characterized cohort of BC patients; however, several inherent limitations should be considered.